On February 27, JPMorgan Chase purchased an additional 408,630 shares of INNOVENT BIO (01801) at a price of HK$84.9352 per share. The total transaction value amounted to approximately HK$34.71 million. Following this acquisition, JPMorgan Chase's total holding in the company reached approximately 86.9081 million shares, representing a 5% stake.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments